Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington’s Disease
UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntington’s disease.
Aitia and G3 Therapeutics Publish Results Identifying New Causal Biomarkers of Atherosclerotic Coronary Artery Disease (ASCAD), the Leading Cause of Morbidity and Mortality Worldwide
G3 Therapeutics, a life sciences company that leverages large-scale multi-omic biological big data to develop life-changing therapeutics and diagnostics, and Aitia, the leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced results of research that identified new causes of ASCAD.
GNS Rebrands as Aitia to Focus on AI-Enabled Drug Discovery
GNS, the leader in the application of causal AI and “Digital Twins” to discover and develop new drugs, announced today its rebranding as Aitia (pronounced “ay-tee-ah”). Aitia, derived from the Greek word for causality, will focus on further leveraging its Gemini Digital Twins to discover the next generation of breakthrough drugs to improve outcomes for patients…
GNS Announces Abstract and Oral Poster Presentation at CTAD & ASH, 2022 Annual Conferences
GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced two abstracts and two oral poster presentations highlighting insight from the Gemini Digital Twin models in Alzheimer’s Disease and Multiple Myeloma will be included at the Clinical Trials on Alzheimer’s Disease conference (CTAD) in San Francisco and the American Society of Hematology (ASH) in New Orleans…
GNS Appoints John Maraganore as Chair of the Board
GNS, the leader in the application of Causal AI and simulation and “Digital Twins” to discover new drugs, today announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, has been appointed as the new GNS Chair of the Board…
GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
GNS and Servier, today announced a collaboration to advance drug discovery, translational, and clinical development efforts in Multiple Myeloma (MM).
GNS Appoints John Maraganore, PhD, as Strategic Advisor
GNS today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined GNS as a strategic advisor.
GNS and the Global Alzheimer’s Platform Foundation® Partner to advance Alzheimer’s R&D
3-year partnership will leverage biomarker database and AI for innovation to create“Digital Twins” that help uncover the complex biology driving Alzheimer’s Disease
GNS Healthcare and Arvinas Enter into Neuroscience Drug Discovery Collaboration
GNS Healthcare, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases…
GNS Healthcare Hires Industry Veteran, Joseph F. Donahue, as Chief Business Officer
GNS Healthcare, the leader in the use of “Virtual Patients”, Causal AI and simulation technology for biopharmaceutical companies, today announced the hiring of Joseph F. Donahue as Chief Business Officer…